Initial antiretroviral therapy in chronically-infected HIV-positive adults

Bibliography

• PALELLA FJ Jr, DELANEY KM, MOORMAN AC et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N EngL I Med. (1998) 338:853–860.
   PubMedGoogle Scholar
• TORRES RA, BARR M: Impact of combination therapy for HIV infection on inpatient census. N Engl. I Med. (1997) 336:1531–1532.
   PubMed Web of Science ®Google Scholar
• CHAISSON MA, BERENSON L, LI W et al.: Accelerating decline in New York City AIDS mortality. In: 5th Conference on Retro viruses and Opportunistic Infections, Foundation for Retrovirology and Human Health, Chicago, USA (1998).
   Google Scholar
• HOGG RS, O'SHAUGHNESSY MV, GATARIC N et al.: Decline in deaths from AIDS due to new antiretrovirals. Lancet (1997) 349:1294–1294.
   Google Scholar
• MOUTON Y, ALFANDARI S,VALETTE M et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS (1997) 11:F101–F105.
   Google Scholar
• BRODT HR, KAMPS BS, GUTE P, KNUPP B, STASZEWSKI S, HELM EB: Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS (1997) 11:1731–1738.
   PubMed Web of Science ®Google Scholar
• EGGER M, HIRSCHEL B,FRANCIOLI P et al.: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br. Med. .1. (1997) 315:1194-1199.
   Google Scholar
• PALELLA FJ Jr, CHMIEL JS,MOORMAN AC, HOLMBERG SD: HIV Outpatient Study Investigators. Durability and predictors of success of highly activeantiretroviral therapy for ambulatory HIV-infected patients. AIDS (2002)16(12):1617–1626.
   Google Scholar
• ERON J, BENOIT S, JEMSEK J et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl. I Med. (1995) 333:1662–1669.
   PubMed Web of Science ®Google Scholar
• KURITZKES DR, MARSCHNER I, JOHNSON VA et al.: Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind placebo-controlled trial AIDS (1999) 13:685–694.
   Google Scholar
• STASZEWSKI S, KATLAMA C, HARRER T et al.: A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS (1998) 12(16):197–202.
   PubMedGoogle Scholar
• BARDITCH-CROVO P, DEEKS SG, COLLIER A et al.: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2001) 45(102733–2739.
   Google Scholar
• DELEHANTY J, WAKEFORD C, QUINN L et al: A Phase I/II Randomized, Controlled Study of FTC Versus 3TC in HIV-Infected Patients. In: ah Conference on Retrovimses and Opportunistic Infections, Foundation for Retrovirology and Human Health, Chicago, USA (1999)(Abstract 16).
   Google Scholar
• PAPA ME MEEHAN P, HOLDEN-WILTSE Jet ai:ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. Antimicrob. Agents Chemother. (1999) 43:1373–1378.
   PubMedGoogle Scholar
• MAYERS D, RIDDLER S, STEIN D et al:A double-blind pilot study to evaluate the antiviral activity, tolerability, and pharmacokinetics of DMP 266 alone and in combination with indinavir. In: Abstracts of the 3ffh Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1996)(Abstract LBO8A).
   Google Scholar
• KITCHEN VS, SKINNER C,ARIYOSHI K et al.: Safety and activity of saquinavir in HIV infection. Lancet (1995) 345:952–955.
   Google Scholar
• DANNER SA, CARR A, LEONARD JM et al.: A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. The European-Australian Collaborative Ritonavir Study Group. N Engl. I Med. (1995) 333:1528–1534.
   PubMed Web of Science ®Google Scholar
• GULICK RM, MELLORS JW, HAVLIR D et al.: Simultaneous versus sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. 100-Week follow-up. JAMA (1998) 280:35–41.
   Google Scholar
• MARKOWITZ M, CONANT M, HURLEY A et al.: A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. I Infect. Dis. (1998) 177:1533–1540.
   PubMed Web of Science ®Google Scholar
• TISDALE M, MYERS S, HARRIGAN PR et al.: Analyses of HIV genotype and phenotype during 4 weeks dose-escalating monotherapy with the HIV protease inhibitor 141W94 in HIV-infected patients with CD4 counts 150-400/mm3. In: 4th Conference on Retro viruses and Opportunistic Infections, Foundation for Retrovirology and Human Health, Washington DC, USA (Abstract 508).
   Google Scholar
• MURPHY RL, BRUN S, HICKS C et al: ABT-378/ritonavir plus stavudine andlamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 15:Fl-F9.
   Google Scholar
• SANNE I, PILIERO P SQUIRES K, THIRY A, SCHNITTMAN S: AI424-007 Clinical Trial Group. Results of a Phase II clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J. Acquit: Immune Defic. Syndr. (2003) 32(1):18–29.
   Google Scholar
• HAMMER SM, KATZENSTEIN DA, HUGHES M D et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl. J. Med. (1996) 335:1081–1090.
   Google Scholar
• KATZENSTEIN DA, HAMMER SM, HUGHES MD et al.: The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. (1996) 335:1091–1098.
   PubMed Web of Science ®Google Scholar
• KURITZKES DR, MARSCHNER I, JOHNSON VA et al.: Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind placebo-controlled trial. AIDS (1999) 13:685–694.
   Google Scholar
• FOUDRAINE NA, DE JONG JJ, JAN WEVERLING G et al.: An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS(1998) 12:1513–1519.
   Google Scholar
• MOLINA JM, CHENE G, FERCHAL F et al.: The ALBI Trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.J. Infect. Dis. (1999) 180:351–358.
   PubMed Web of Science ®Google Scholar
• CARR A, CHAUH J, HUDSON J et al.:A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombol study. AIDS (2000) 14:1171–1180.
   PubMed Web of Science ®Google Scholar
• SQUIRES, KE, GULICK R, TEBAS P et al.: A comparison of stavudine plus lamivudine versus zidovudine pluslamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS (2000) 14:1591–1600.
   PubMed Web of Science ®Google Scholar
• ERON JJ, MURPHU RL, PETERSON D et al.: A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II). AIDS (2000) 14: 1601-1600.
   Google Scholar
• STASZEWSKI S, GALLANT JE, POZNIAK AL et al.: Efficacy and safety of tenofovir DF versus stavudine when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results. In: Program and abstracts of the 1(1" Conference on Retro viruses and Opportunistic Infections, Boston, USA (2003) (Abstract 5646).
   Google Scholar
• DEJESUS E, HERRERA G, TEOFILO E et al.: Efficacy and safety of abacavir (ABC) versus zidovudine (ZDV) in antiretroviral therapy naive adults with HIV-1 infection. In: Program and abstracts of the 4.7d Annual ICAAC, Chicago, Illinois, USA(Abstract H–446).
   Google Scholar
• RAFFI F, SAAG M, CAHN P et al: A Randomized, double-blind, multicenter comparison of emtricitabine qd to stavudine BID in treatment naïve HIV-infected patients. In: Program and abstracts of the The IAS Conference on HIV Pathogenesis and Treatment, Paris, France (2003)(Abstract 38).
   Google Scholar
• SANNE I, VAN DER HORST C, SHAW A et al.: Two randomized, controlled, equivalence trials of emtricitabine (FTC) to lamivudine (3TC). In: Program and abstracts of the XIV International AIDS Conference, Barcelona, Spain (2002) (Abstract TuPeB4432).
   Google Scholar
• GULICK RM, RIBAUDO HJ,SHIKUMA CM et al: ACTG 5095: A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. In: Program and abstracts of the 2'd IAS Conference on HIV Pathogenesis and Treatment, Paris, France (2003) (Abstract 41).
   Google Scholar
• GALLANT JE, RODRIGUEZ AE, WEINBERG W et al.: Early Non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: E5530009. In: Program and abstractsof the 4.7d Annual ICAAC, Chicago, USA (2003) (Abstract 1722a).
   Google Scholar
• FARTHING C, KHANLOU H, YEH V: Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. In: Program and abstracts of the 2'd IAS Conference on HIV Pathogenesis and Treatment, Paris, France (2003) (Abstract 43).
   Google Scholar
• KING RW, KLABE RM, REID CD, ERICKSON-VIITANEN SK: Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob. Agents Chemother. (2002) 46(6):1640–1646.
   PubMedGoogle Scholar
• MONTANER JS, REISS P, COOPER D, VELLA S et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA (1998) 279(12):930–937.
   Google Scholar
• HARRIS M, PATENAUDE P, COOPERBERG P et al.: Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. INCAS Study Group. Italy, Netherlands, Canada, Australia, and (United) States. J. Infect. Dis. (1997) 176(5):1388–1392.
   Google Scholar
• SQUIRES K, for the ATLANTIC STUDY TEAM: The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, final 48 week data. In: Program and abstracts of the XIII International AIDS Conference, Durban, South Africa (2000) (Abstract LbPeB7046).
   Google Scholar
• VAN DER VALK M, KASTELEIN JJ, MURPHY RL et al: The Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.AIDS (2001) 15(18):2407–2414.
   Google Scholar
• PODZAMCZER D, FERRER E, CONSIGLIO E et al.: A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir. Ther: (2002) 7(2):81–90.
   PubMed Web of Science ®Google Scholar
• BARTLETT JA, JOHNSON J, HERRERA G et al.: Abacavir/lamivudine(ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS) preliminary 48 week results. In: Program and abstracts of the The XIV International AIDS Conference, Barcelona, Spain (2002) (Abstract TuOrB1189).
   Google Scholar
• STASZEWSKI S, MORALES-RAMIREZ J,TASHIMA KT et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl. J. Med. (1999) 341(25):1865–1873.
   Google Scholar
• TASHIMA K, STASZEWSKI S, MORALES-RAMIREZ J et al.: 3-Year Durability Of Response With An Efavirenz (Efv)-Containing Regimen: 144 Week Follow-Up Of Study 006. In: Program and abstracts of the P IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina (2001) Abstract no. 224.
   Google Scholar
• MATTHEWS GV, SABIN CA, MANDALIA S et al.: Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 16:53–61.
   PubMed Web of Science ®Google Scholar
• KEISER, P, NASSAR N, WHITE C, KOEN G, MORENO S: Comparison of Nevirapine-and Efavirenz- containing antiretrovral regimens in antiretroviral-naïve patients: a cohort study. HIV Clin. Trials (2002) 3(4):296–303.
   PubMedGoogle Scholar
• COZZI-LEPRI A, PHILLIPS AN, D'ARMINIO MONFORTE AD et al: Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian cohort naïve antiretrovirals (I.Co.N.A) study. J. Infect. Dis. (2002) 185:1062–1069.
   PubMed Web of Science ®Google Scholar
• NUNEZ M, SORIANO V, MARTIN-CARBONERO L et al.: SENC (Spanish efavirenz versus nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals.HIV Clin. Trials (2002) 3(3):186–194.
   Google Scholar
• VAN LEITH F, HASSINK E,PHANUPHAK P et al.: Results of the 2NN Study: A randomized, comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. In: Program and abstracts of the lab Conferenceon Remo viruses andOpportunistic Infections, Boston, USA (2003) (Abstract 176).
   Google Scholar
• ROBBINS GK, DE GRUTTOLA V, SHAFER RW et al. For the AIDS Clinical Trials Group 384 Team: Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. N Engl. J Med. (2003) 349:2293–2303.
   PubMed Web of Science ®Google Scholar
• SHAFER RW, SNYDER SW,ROBBINS GK et al For the AIDS Clinical Trials Group 384 Team: Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. N Engl. J Med. (2003) 349:2304–2315.
   PubMed Web of Science ®Google Scholar
• SENSION MG, FARTHING C, SHAFFER AG et al.: Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study. AIDS Patient Care STDS (2001) 15:129.
   PubMedGoogle Scholar
• MATHEZ D, BAGNARELLI P, GORIN I et al.: Reductions in viral load and increases in T lymphocyte numbers in treatment naïve patients with advanced HIV infection treated with ritonavir, zidovudine, and zalcitabine triple therapy. Antivir: Titer. (1997) 2:175.
   PubMedGoogle Scholar
• STASZEWSKI S, KEISER P, MONTANER J et al.: Abacavir-lamivudine-zidovudine versus indinavir-lamivudine-zidovudine in antiretroviral-naive hiv-infected adults: a randomized equivalence trial. JA/VIA (2001) 285:1155–1163.
   Google Scholar
• WALMSLEY S, BERNSTEIN B, KING M et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl. J. Med. (2002) 346:2039–2046.
   PubMed Web of Science ®Google Scholar
• SANNE I, CAHN P, PERCIVAL L, and the BMS-008 International Trial Group: Atazanavir versus nelfinavir in combination with stavudine and lamivudine in treatment-naive HIV-Infected Patients, 48-week results. In: Programs and abstracts of the 4t Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2001) (Abstract 1–667).
   Google Scholar
• SQUIRES KE, THIRY A,GIORDANO M: Atazanavir (ATV) QD and efavirenz (EFV) AQ with fixed-dose ZDV + 3TC: comparison of antiviral efficacy and safety through Wk 24 (AI424-034). In: Programs and abstracts of the 42'd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA (2002) (Abstract H–1076).
   Google Scholar
• RODRIGUEZ-FRENCH A,BOGHOSSIAN J, GRAY GE et al, the NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J. Acquit: Immune Defic. Syndr: (2004) 35(1):22–32.
   PubMed Web of Science ®Google Scholar
• SCHURMANN D, GATHE J, SANNE J,WOOD R: Efficacy and safety of GW433908/ritonavir once daily in therapy-naïve subjects, 48 week results: the SOLO study. Program and abstracts of the ah International Congress on Drug Therapy M HIV Infection, Glasgow, Scotland. November 17-21(2002)(Abstract PL14.4).
   Google Scholar
• D'ARMINIO MONFORTE A,LEPRI AC, REZZA G et al: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral-naïve patients. AIDS (2000) 14:499–507.
   PubMed Web of Science ®Google Scholar
• SULKOWSKI MS, THOMAS DL, MEHTA SH, CHAISSON RE,MOORE RD: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 35(1):182–189.
   PubMed Web of Science ®Google Scholar
• NUNEZ M, LANA R, MENDOZA JL, MARTIN-CARBONEROL, SORIANO V: Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2001) 27(5):426–431.
   PubMedGoogle Scholar
• Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000. MMWR Morb. Mortal. Wkly Rep. (2001) 49(51-52):1153–1156.
   PubMedGoogle Scholar
• DE SANTIS M, CARDUCCI B, DE SANTIS L, CAVALIERE AF,STRAFACE G: Periconceptional exposure to efavirenz and neural tube defects.Arch. Intern. Med. (2002) 162(3):355.
   Google Scholar
• FUNDARO C, GENOVESE 0, RENDELI C, TAMBURRINI E, SALVAGGIO E: Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS (2002) 16(2):299–300.
   PubMed Web of Science ®Google Scholar
• ACETI A, PASQUAZZI C, ZECHINI B, DE BAC C, LIVERHAART Group: Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. I. Acquit: Immune Defic. Syndr. (2002) 29(1):41–48.
   PubMed Web of Science ®Google Scholar
• BONFANTI P, LANDONIO S, RICCI E, The CISAI study group: risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. Acquir. Immune Defic. Syndr. (2001) 27(3):316–318.
   PubMed Web of Science ®Google Scholar
• FELLAY J, BOUBAKER K,LEDERGERBER B et al.: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 358:1322–1327.
   Google Scholar
• MATTHEWS GV, MOYLE GJ,MANDALIA S, BOWER M, NELSON M, GAZZARD BG: Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. j Acquir. Immune Defic. Syndr: (2000) 24:310–315.
   Google Scholar
• KUMAR P, RODRIGUEZ-FRENCH A, THOMPSON M et al: Prospective study of hyperlipidemia in ART-naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (E5540002). In: Program and abstracts of the gh Conference on Retroviiuses and Opportunistic Infections, Seattle, USA (2002):64 (Abstract 33).
   Google Scholar
• TASHIMA K, STRYKER R, SKIEST D et al.: Lipid profiles & clinical lipodystrophy in study 006 patients. In: Programs and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (1999) (Abstract 1304).
   Google Scholar
• VAN DER VALK M, KASTELEIN JJ, MURPHY RL et al.: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 15:2407–2414.
   Google Scholar
• VAN LETH F, PHANUPHAK P, GAZZARD B et al: Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine(2NN Study). In: Program and abstracts of the lath Conference on Retroviiuses and Opportunistic Infections, Boston, USA (2003):328 (Abstract 752).
   Google Scholar
• PERIARD D, TELENTI A, SUDRE P et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV cohort study. Circulation (1999) 100:700–705.
   PubMed Web of Science ®Google Scholar
• DUBE. MP, QIAN D, EDMONDSON-MELAKON H et al.: Prospective,48-week, intensive metabolic study of amprenavir-based therapy. Clin. Infect. Dis. (2002) 35:475–481.
   Google Scholar
• SEGERER S, BOGNER JR, WALLI R, LOCH 0, GOEBEL FD: Hyperlipidemia under treatment with proteinase inhibitors. Infection (1999) 27:77–81.
   PubMed Web of Science ®Google Scholar
• MOYLE GJ, BALDWIN C: Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy. Acquir. Immune Defic. Syndr. (1999) 21:423–424.
   PubMedGoogle Scholar
• CASTAGNA A, DRAGSTED UB, CHAVE JP et al.: The interim analysis of a phase iv randomised, open-label, multicentre trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg BID) versus saquinavir/ritonavir(1000/100 mg MID) in Adult HIV-1 infection: MaxCmin1 Trial. In: Program and abstracts of the gh Conference on Retrovimses and Opportunistic Infections, Boston, USA (2002) (Abstract 752).
   Google Scholar
• GATELL J, SQUIRES K, PILIERO P, SANNE I, WOOD R,SCHNITTMAN SM: Atazanavir (BMS-232632): Absence of serum lipid changes after 48 weeks of treatment in treatment-naive HIV-positive subjects (Trial AI424-007). Antivir:Ther. (2001) 6\(Suppl. 4):49.
   Google Scholar
• DUBE. MP, EDMONDSON-MELANCON H, QIAN D, AQEEL R, JOHNSON D, BUCHANAN TA: Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. I Acquir: Immune Defic. Syndr. (2001) 27:130–134.
   PubMedGoogle Scholar
• CARR A, SAMARAS K, CHISHOLM DJ, COOPER DA: Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet (1998) 351: 1881-1883.
   Google Scholar
• DUBE MP, JOHNSON DL,CURRIER JS, LEEDOM JM: Protease inhibitor-associated hyperglycaemia. Lancet (1997) 350:713–714.
   PubMed Web of Science ®Google Scholar
• CARR A, SAMARAS K, BURTON S et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12:F51–F58.
   PubMed Web of Science ®Google Scholar
• MULLIGAN K, GRUNFELD C, TAI VW et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.Acquir: Immune Defic. Syndr: (2000) 23:35–43.
   PubMed Web of Science ®Google Scholar
• WALLI R, HERFORT 0, MICHL GM et al.: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS (1998) 12:F167–F173.
   Google Scholar
• BEHRENS G, DEJAM A, SCHMIDT H et al.: Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS (1999) 13:F63–F70.
   PubMed Web of Science ®Google Scholar
• MURATA H, HRUZ PW, MUECKLER M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. (2000) 275:20251–0254.
   PubMed Web of Science ®Google Scholar
• MILLER JE, EMERY S, FRENCH M et al.: The Australian prevalence survey of lipodystrophy syndrome. In: Programs and abstracts of the 7th Conference on Retroviiuses and Opportunistic Infections, San Francisco, CA, USA (2000) (Abstract 201).
   Google Scholar
• LICHTENSTEIN KA, WARD DJ, MOORMAN AC et al.: Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS (2001) 15:1389–1398.
   PubMed Web of Science ®Google Scholar
• BERNASCONI E, BOUBAKER K, SUDRE P et al.: Metabolic side effects of antiretroviral therapy in the Swiss Cohort Study. In: Programs and abstracts of the XIII International AIDS Conference, Durban, South Africa (2000) (Abstract ThOrB703).
   Google Scholar
• GERVASONI C, RID OLFO AL, TRIFIRO G et al.: Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.AIDS (1999) 13:465–471.
   PubMed Web of Science ®Google Scholar
• MALLAL SA, JOHN M, MOORE CB et al.: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS (2000) 14:1309.
   PubMed Web of Science ®Google Scholar
• MULLIGAN K, TAI VW, ALGREN H et al.: Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. j Acquir: Immune Defic. Syndr. (2001) 26:443–448.
   PubMed Web of Science ®Google Scholar
• SAINT-MARC T, PARTISANI M, POIZOT-MARTIN I, TOURAINE JL: Reversibility of peripheral fat wasting (lipodystrophy) on stopping stavudine therapy. In: Program and abstracts of the 2' Conference on Retrovimses and OpportunisticInfections, San Francisco (2000) (Abstract 52).
   Google Scholar
• LONERGAN JT, HAVLIR D, BARBER E, MATHEWS WC: Incidence and outcome of hyperlactatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containing regimens. In: Program and abstracts of the 8th Conference on Remo viruses and Opportunistic Infections, Chicago, USA (2001)(Abstract 624).
   Google Scholar
• JOHN M, MOORE CB, JAMES IR et al.: Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS (2001) 15:17–23.
   PubMedGoogle Scholar
• BRINKMAN K, TER HOFSTEDE HJM, BURGER DM, SMEITINK JAM, KOOPMANS PP: Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS (1998) 12:1735–1744.
   PubMed Web of Science ®Google Scholar
• WALKER UI, SETZER B,VEENHOFF N: Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS(2002) 16(16):2165–2173.
   PubMedGoogle Scholar
• GLESBY MJ: Bone disorders in human immunodeficiency virus infection. Clin. Infect. Dis. (2003) 37\(Suppl. 2):591–595.
   Google Scholar
• THOMAS J, DOHERTY SM: HIV infection-a risk factor for osteoporosis. Acquir: Immune Defic. Syndr: (2003) 33(3):281–291.
   PubMed Web of Science ®Google Scholar
• TEBAS P, POWDERLY WG,CLAXTON S et al.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 14:F63–F67.
   Google Scholar
• HOLMBERG SD, MOORMAN AC, WILLIAMSON JM et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet (2002) 360: 1747-1748.
   Google Scholar
• MARY-KRAUSE M, COTTE L, PARTISANI M, SIMON A, COSTAGLIOLA D: Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men. In: Program and abstracts of the 8th Conference on Remo viruses and Opportunistic Infections, Alexandria, VA, USA. Foundation for Retrovirology and Human Health (2001) (Abstract 657).
   Google Scholar
• FRIIS-MOLLER N, SABIN CA, WEBER R: Combination antiretroviral therapy and the risk of myocardialainfarction. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. N EngI.j Med. (2003) 349(21):1993–2003.
   Google Scholar
• BOZZETTE SA, AKE C, CARPENTER A et al.: Cardio- and cerebrovascular outcomes with changing process of anti-HIV therapy in 36,766 US veterans. In: Program and abstracts of the gh Conference on Retro viruses and Opportunistic Infections, Alexandria, VA, USA. Foundation for Retrovirology and Human Health (2002) (Abstract LB–9).
   Google Scholar
• DEEKS SG, SMITH M, HOLODNIY M, KAHN JO: HIV-1 protease inhibitors. A review for clinicians. JAMA (1997) 277:145–153.
   PubMed Web of Science ®Google Scholar
• BECKER SL: The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy.Expert Opin. Investig. Drugs (2003) 12(3):401–412.
   Google Scholar
• MOYLE G: The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs (2001) 61(1):19–26.
   PubMedGoogle Scholar
• KEARNEY BP, ISAACSON E, SAYRE J, PLUMMER A, CHENG A: Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. In: Program and abstracts of the 10h Conference on Remo viruses and Opportunistic Infections, Boston, USA, Alexandria, VA. Foundation for Retrovirology and Human Health (2003):245 (Abstract 533).
   Google Scholar
• TABURET AM, PIKETTY C, GÈRARD L et al.: Pharmacolkinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: a sub-study of Puzzle-2-ANRS 107 trial. In: Program and abstracts of the 10th Conference on Retrovimses and Opportunistic Infections, Boston, USA. Alexandria, VA. Foundation for Retrovirology and Human Health, (2003):247 (Abstract 537).
   Google Scholar
• DAQUILA RT, SCHAPIRO JM, BRUN-VEZINET F, CLOTET B: Drug resistance mutations in HIV-1. Top. HIV Med. (2003) 11(3):92–96.
   PubMedGoogle Scholar
• SORIANO V, DE MENDOZA C: Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clin. Trials (2002) 3(3):237–248.
   PubMedGoogle Scholar
• TEBAS P, POWDERLY WG: Nelfinavir mesylate. Expert Opin. Pharmacother. (2000) 1:1429–1440.
   PubMedGoogle Scholar
• TEBAS P, PATICK AK, KANE EM et al.: Virologic re-sponses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS (1999) 13:F23–28.
   Web of Science ®Google Scholar
• KEMPF D, KING M, BAUER E et al: Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir/ritonavir or nelfinavir as initial therapy. In: Program and abstracts of the 1U' Conference on Retro viruses and Opportunistic Infections, Boston, USA (2003)a(Abstract 600).
   Google Scholar
• CVETKOVIC RS, GOA KL:Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs (2003) 63(8):769–802.
   PubMed Web of Science ®Google Scholar
• PRADO JG, VVRIN T, BEAUCHAINE J et al.: Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS (2002) 16(7):1009–1017.
   PubMedGoogle Scholar
• COLONNO R, ROSE R, CIANCI C, ALDROVANDI G, PARKIN N, FRIBORG J: Emergence of atazanavir resistance and maintenance of susceptibility to other PIs is associated with a 150L substitution in HIV protease. In: Program and abstracts of the 10-h Conference on Remo viruses and Opportunistic Infections Boston, Massachusetts, USA (2003) (Abstract 597).
   Google Scholar
• COLONNO RJ. THIRY A. LIMOLI K. PARKIN N: Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus Type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob. Agents Chemother: (2003) 47(4):1324–1333.
   PubMed Web of Science ®Google Scholar
• YENI PG, HAMMER SM,CARPENTER CCJ et al: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 288:222–235.
   PubMed Web of Science ®Google Scholar
• http: \\www.aidsinfo.nih.org Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection: guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. July 14 (2003).
   Google Scholar
• http: \\www.bhiva.org BHIVA Writing Committee on behalf of the BHIVA Executive Committee: BritishHIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. July 2003.
   Google Scholar